MGI partner Vision Medicals has received NMPA approval for its Respiratory Pathogen Nucleic Acid Detection Kit (cPAS) for clinical application.

MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and has established research, manufacturing, training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGl empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGl also stands out as one of the only providers of a full-stack product portfolio that spans three core segments: SEQ ALL (short-and long-read sequencing),GLI (Generative Lab Intelligence), and Multi-Omics.